Clinical trials: Inflammatory Disease
Crohn's Disease
A Study of Vedolizumab in Adults With Crohn's Disease (CD)
The main aim of this study is to see if adults with CD treated with vedolizumab have less symptoms and inflammation of the bowel assessed by ultrasonography.
- Trial name
- SUNRISE (NCT05192863)
- Testing
- No Intervention
- Where
- 10 sites in Canada, Israel and 1 more
- Volunteers
- 72 people
- Sponsor
- Takeda
Moderately to Severely Active Crohn Disease
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and…
- Trial name
- ENHANCE-CD (NCT06456593)
- Testing
- Obefazimod
- Where
- 149 sites in United States, Belgium and 10 more
- Volunteers
- 212 people
- Sponsor
- Abivax S.A.
Crohn Disease, Colitis, Ulcerative
A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
The purpose of this study is to find out how long a participant keeps taking guselkumab or continues with their treatment plan without stopping (treatment persistence) in participants with moderate to severe Crohn's disease (CD)…
- Trial name
- GusTaCon (NCT07746765)
- Volunteers
- 35 people
- Sponsor
- Janssen Sciences Ireland UC
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Asthma
Unrefined Salmon Oil as Dietary Supplement in Adult Asthmatics
Research has over decades showed that marine food carries nutritional characteristics that promote human health. As seen in epidemiological studies and based on in vitro and in vivo studies, it is hypothesized that unrefined…
- Trial name
- NCT05137132
- Testing
- CARDIO®
- Where
- Norway
- Volunteers
- 70 people
- Sponsor
- Hofseth Biocare ASA
Rheumatoid Arthritis
Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94
Study 1304 is a Phase I dose escalation study conducted in adults with persistent moderate (grade 2) or severe (grade 3) swelling due to inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, or ankylosing…
- Trial name
- NCT00617032
- Testing
- tgAAC94 gene therapy vector
- Where
- 7 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Targeted Genetics Corporation
Crohn Disease
Open-label Trial of Leukine in Active Crohn's Disease
The purpose of this study is to establish a safety profile sargramostim administered in 8 week cycles to adult patients with active Crohn's disease.
- Trial name
- NCT00206700
- Testing
- Sargramostim (Leukine)
- Where
- 167 sites in United States, Argentina and 8 more
- Volunteers
- 378 people
- Sponsor
- Genzyme, a Sanofi Company
Crohn's Disease
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's…
- Trial name
- DIVERSITY LTE (NCT02914600)
- Testing
- Filgotinib
- Where
- 486 sites in United States, Argentina and 38 more
- Volunteers
- 1,188 people
- Sponsor
- Lakefront Biotherapeutics NV
Inflammatory Bowel Diseases, Blau Syndrome
Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants
First-in-human study to provide an assessment of the safety, tolerability, pharmacokinetics (PK), including food effects and a drug-drug interaction, and pharmacodynamics (PD) of OD-07656 after administration of ascending single…
- Conditions
- Inflammatory Bowel Diseases, Blau Syndrome, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT06206811
- Testing
- OD-07656
- Where
- Australia
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Odyssey Therapeutics, Inc.
Crohn Disease
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy of JNJ-active as measured by the change in the Crohn's Disease Activity Index (CDAI) score and Simplified Endoscopic Score for Crohn's disease (SES-CD) from baseline at Week…
- Trial name
- PRISM (NCT04102111)
- Testing
- JNJ-67864238
- Where
- 63 sites in United States, Argentina and 5 more
- Volunteers
- 48 people
- Sponsor
- Janssen Research & Development, LLC
Macula Edema, Radiation Retinopathy
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the…
- Conditions
- Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane
- Trial name
- NCT04120636
- Testing
- Episcleral Celecoxib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Targeted Therapy Technologies, LLC
Crohn's Disease
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
The purpose of this study is to prospectively evaluate a scoring system to predict a mild course of disease in patients newly diagnosed with Crohn's disease.
- Trial name
- PROGNOS (NCT02193048)
- Testing
- This study will evaluate a new clinical scoring system in patients receiving routine treatment
- Where
- Germany
- Volunteers
- 216 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis
Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults
This study will estimate the absolute bioavailability of subcutaneously injected GS-5745, characterize the safety, tolerability, and pharmacokinetics (PK) of GS-5745 after subcutaneous (SC) injection and intravenous (IV)…
- Trial name
- NCT02209987
- Testing
- GS-5745 SC, GS-5745 IV
- Where
- New Zealand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Ulcerative Colitis
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis
This study will evaluate the efficacy, safety and tolerability of AEB071 in the treatment of active, moderate to severe ulcerative colitis in patients who have failed conventional therapy using mesalamine or steroids
- Trial name
- NCT00572585
- Testing
- AEB071
- Where
- 20 sites in United States, Denmark and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Non-inflammatory Degenerative Joint Disease (NIDJD), Avascular Necrosis
Sidus(TM) Post Market Clinical Follow-up (PMCF) Study
This post market clinical follow-up study is designed to confirm safety and performance of the Sidus Stem-Free Shoulder when used in hemi or total shoulder arthroplasty.
- Conditions
- Non-inflammatory Degenerative Joint Disease (NIDJD), Avascular Necrosis, Osteoarthritis, Inflammatory Joint Disease (IJD)
- Trial name
- NCT01700543
- Testing
- Shoulder Arthroplasty
- Where
- 8 sites in Austria, France and 3 more
- Volunteers
- 152 people
- Sponsor
- Zimmer Biomet
Pulmonary Disease, Chronic Obstructive
A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients
It is hypothesised that there is a difference between the uptake of a radioactive substance ([18F]fluorodeoxyglucose (FDG)) in the lungs of patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy volunteers.
- Trial name
- NCT00472264
- Testing
- PET imaging
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Crohn's Disease
Bologna IBD Markers
Individuate possible predictive factors of anti-TNFalfa-induced deep remission in Crohn's disease.
- Trial name
- NCT02580864
- Where
- Italy
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Atherosclerosis, Inflammatory Activity in Carotid Arteries
Effects of Crestor on Inflammation of Atherosclerotic Plaques
The primary aim of this study is to investigate the effect of 40 mg dose of rosuvastatin on carotid plaque inflammation measured with MRI and PET scanning, to evaluate whether these techniques are promising for future proof of…
- Trial name
- NCT00689416
- Testing
- rosuvastatin
- Where
- Sweden
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acute Gout
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom…
- Trial name
- β-RELIEVED (NCT01029652)
- Testing
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg
- Where
- 47 sites in Australia, Belgium and 15 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease
This is a multicenter, Phase 1b, randomized, double-blind, placebo-controlled, sequential-cohort, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of 3…
- Trial name
- NCT02249078
- Testing
- E6011
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.